Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT01100814
First received: September 15, 2009
Last updated: January 21, 2014
Last verified: January 2014
  Purpose

The investigators hypothesize that aberrant hypermethylation of tumour suppressor genes is an important mechanism for Epstein-Barr Virus (EBV) - related gastric carcinogenesis, the promoter hypermethylation status and the expression of S100A2 and TFF1 might be different between EBV-associated gastric cancer (GC) and non EBV-associated GC.


Condition
Gastric Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer

Resource links provided by NLM:


Further study details as provided by National University Hospital, Singapore:

Study Start Date: September 2011
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

200 gastric tumour and normal tissue samples, as well as up to 50 non-neoplastic gastric tissues samples from individuals without gastric cancer (treated for other reasons, such as gastric ulcers) will be obtained from the tissue archives of the NUH Department of Pathology. These samples were selected because relevant clinical information of these samples are available from gastric database and will allow us to perform association studies.

Criteria

Inclusion Criteria:

  • Nil

Exclusion Criteria:

  • Nil
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01100814

Locations
Singapore
National University Hospital
Singapore, Singapore, 119074
Sponsors and Collaborators
National University Hospital, Singapore
  More Information

No publications provided

Responsible Party: Wei Peng Yong, National University Hospital, Singapore
ClinicalTrials.gov Identifier: NCT01100814     History of Changes
Other Study ID Numbers: GA01/08/08
Study First Received: September 15, 2009
Last Updated: January 21, 2014
Health Authority: Singapore: Domain Specific Review Boards

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases

ClinicalTrials.gov processed this record on August 26, 2014